8-K: Catheter Precision Details Significant Share Dilution from At-The-Market Offering

Catheter Precision, Inc. has filed an 8-K detailing the significant dilution new investors will face from its ongoing at-the-market common stock offering, alongside updates to its negative net tangible book value.

Summary

• Catheter Precision, Inc. (VTAK) filed an 8-K to provide dilution information for its outstanding registration statements.
• As of March 31, 2025, the company's net tangible book value was negative $15.8 million, or negative $1.71 per share, based on 9,268,632 shares outstanding.
• After accounting for the issuance of 1,748,666 shares in April 2025, the pro forma net tangible book value as of March 31, 2025, was negative $15.84 million, or negative $1.44 per share, based on 11,017,298 adjusted shares outstanding.
• The company's current at-the-market (ATM) offering involves the sale of 4,333,333 shares of common stock at an assumed price of $0.30 per share, which was the last reported sale price on the NYSE American on May 14, 2025.
• This ATM offering is expected to generate estimated net proceeds of $1.2 million after deducting commissions and offering expenses.
• After giving effect to the ATM offering, the pro forma as adjusted net tangible book value as of March 31, 2025, would be negative $14.6 million, or negative $0.95 per share.
• This adjustment represents an immediate increase in net tangible book value of $0.49 per share for existing stockholders.
• However, it also represents an immediate and substantial dilution of negative $1.25 per share for new investors purchasing shares at the assumed public offering price of $0.30.
• The company also detailed a significant number of shares reserved for future issuance, including 1,641,184 shares for outstanding options, 525,000 shares for non-plan options, 33,335 shares for restricted stock awards, and 17,385,613 shares for outstanding warrants (including 1,425,000 pre-funded warrants with no exercise price), as well as 880,365 additional shares for future equity incentive plans, all as of March 31, 2025.

Sentiment

Score: 3

Explanation: The document primarily focuses on the negative impact of dilution for new investors and the company's persistently negative net tangible book value, despite the capital raise. While capital is being raised, the terms and existing financial state suggest a challenging outlook for new equity holders.

Positives

• The at-the-market offering is expected to generate $1.2 million in estimated net proceeds, providing additional capital to the company.
• Existing stockholders are expected to see an immediate increase in net tangible book value of $0.49 per share due to the pro forma adjustments and the ATM offering.

Negatives

• The company's net tangible book value remains significantly negative, at negative $15.8 million as of March 31, 2025, and projected to be negative $14.6 million after the ATM offering.
• New investors purchasing shares in the ATM offering at the assumed price of $0.30 per share will experience an immediate and substantial dilution of negative $1.25 per share.
• The company's historical and pro forma net tangible book value per share are negative, indicating that liabilities exceed tangible assets.

Risks

• Future exercise of outstanding stock options or warrants, conversion of preferred stock, or issuance of new equity/convertible debt securities at a price less than the offering price could lead to further dilution for new investors.
• The actual public offering price and other terms of any offering may vary, affecting the final dilution figures.
• The company may choose to raise additional capital in the future due to market conditions or strategic considerations, which could result in further dilution to stockholders if raised through equity or convertible debt securities.

Future Outlook

The company anticipates that the dilution information will adjust based on the actual public offering price and other terms of any future offerings. It also notes that further dilution to new investors could occur if outstanding stock options or warrants are exercised, preferred stock is converted, or additional shares of common stock are issued in the future at a price less than the offering price. The company may also choose to raise additional capital due to market conditions or strategic considerations, which could lead to further dilution if raised through equity or convertible debt securities.

Management Comments

• The report was signed by Philip Anderson, Chief Financial Officer of Catheter Precision, Inc.

Industry Context

This filing primarily focuses on the company's capital structure and dilution effects of its equity offering, rather than broader industry trends. It is a standard disclosure for companies undertaking 'at-the-market' offerings to inform investors about potential dilution.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Existing stockholders will see a slight increase in net tangible book value per share ($0.49), but new investors will experience significant immediate dilution (negative $1.25 per share). All stockholders face potential future dilution from further equity issuances or exercise of outstanding securities.
• Creditors: The capital raise may slightly improve the company's liquidity, potentially reducing immediate credit risk, but the persistently negative net tangible book value indicates a weak underlying financial position.

Next Steps

• The company will continue to sell shares from time to time at various prices through its at-the-market offering.
• The company may consider raising additional capital in the future based on market conditions or strategic needs.

Key Dates

Recommendation

Keywords

Catheter Precision, VTAK, SEC filing, 8-K, dilution, at-the-market offering, ATM offering, common stock, net tangible book value, capital raise, equity offering, shares outstanding, warrants, stock options